A potential biomarker for survival for non-metastatic kidney cancer

A recent study published in the journal International Urology and Nephrology this month evaluates mean platelet volume-to-lymphocyte ratio (MPVLR) as a biomarker for survival in patients undergoing nephrectomy for non-metastatic clear cell renal cell carcinoma (ccRCC). In the study, 344 patients with proven ccRCC that has not spread (non-metastatic) were treated with radical or partial […]

read more

C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more

Neutrophil-lymphocyte ratio for predicting survival in sarcomatoid kidney cancer

A recent study of 230 patients with sarcomatoid renal cell carcinoma (RCC) investigated pre-surgery neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio as biomarkers for the prediction of survival. Neutrophil-lymphocyte ratio was assessed 1 to 8 weeks after surgery, and percentage change from pre- to post-surgery was calculated. Pre-surgery neutrophil-lymphocyte ratio was a significant predictor of […]

read more

Predictive biomarkers for kidney cancer

At the Society of Urologic Oncology (SUO) conference in Washington, USA last week, Dr Joshua Lang discussed the future of predictive biomarkers in renal cell carcinoma (RCC). The treatment of kidney cancer is evolving with first-line combination therapies, including nivolumab plus ipilimumab and axitinib plus pembrolizumab, and first-line drug options that depend on risk of […]

read more

Prognostic implications of aquaporin 9 expression in kidney cancer

Water channel proteins, or aquaporins (AQPs) have been found in large amounts in tumour samples and have a role in the progression of cancer. This study looked at the messenger RNA (mRNA) expression for AQP9 and how this related to survival for patients with renal cell carcinoma (RCC). The data for this study came from […]

read more

IKCS 2019: Novel biomarkers for prognosis of kidney cancer

Two presentations at the International Kidney Cancer Symposium 2019 in Miami earlier this month discuss the use of two novel biomarkers for imaging metastatic renal cell carcinoma (RCC). Dr Allan Pantuck from the University of California, Los Angeles spoke about carbonic anhydrase IX (CAIX) as a non-invasive molecular marker for clear cell RCC. Tumours that […]

read more

IKCS 2019: Biomarkers in kidney cancer

In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study. Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating […]

read more

Effect of weight loss during treatment with targeted therapy

This large retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) was designed to investigate the effect of weight change on overall survival in patients treated with targeted therapy. During 12 weeks after starting first- or second-line treatment with a targeted therapy, 28% of patients had lost weight and 58% had stable weight. […]

read more

Potential prognostic marker for kidney cancer

A recent study to be published in Clinical and Experimental Medicine next month investigates the role of microRNAs (miRNAs) in the development of renal cell carcinoma (RCC) and the levels of miRNA-15a in RCC tumours. The investigators showed that increased miRNA-15a was associated with indicators of poor prognosis, such as high Fuhrman grade, the presence […]

read more

Liquid biopsies in the era of immuno-oncology

This review, published in the Annals of Oncology, discusses the role of liquid biopsies in the field of immuno-oncology to predict response, relapse or adverse events in cancer patients treated with immunotherapy. A liquid biopsy is a test done on a sample of blood to look for cancer cells from a tumour that are circulating […]

read more
Showing 1 to 10 of 51 results
  TOP